Global and Regional Transplant Diagnostics

Transplant Diagnostics Comprehensive Study by Type (Instrument, Reagent, Software), Application (Human Leukocyte Antigen (HLA), Blood Profile, Pathogen Detection), Organ Type (Heart, Kidney, Liver, Stem Cell), Technology (Molecular Assay Technologies, Non-Molecular Assay Technologies), Screening Method (Pre Transplantation Screening, Post Transplantation Screening), End User (Hospital & Transplant Centers, Commercial Service Providers, Academics & Research Laboratories) Players and Region - Global Market Outlook to 2026

Transplant Diagnostics Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 7.9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Growing number of patients suffering from chronic diseases frequently leading to organ failure will help to boost global transplant diagnosis market. Transplantation diagnosis is a surgical process that contains the replacement of damaged or failed cell, tissue, or organ from same individual or different individual of same or different species. The transplantation diagnostics market is booming due to the increasing patient base for chronic disease all over the world, rising elderly population, and the growing number of organ transplantation diagnosis processes. The transplant diagnosis market in emerging countries is estimated to grow during the forecast period due the growing healthcare awareness and the increasing healthcare spending.
According to AMA, the market for Transplant Diagnostics is expected to register a CAGR of 7.9% during the forecast period to 2026. This growth is primarily driven by Growing Instances of Organ Failures with Escalating Chronic Failures and Increasing Demand for Pre Transplantation Diagnostics.

Globally, a noticeable market trend is evident Introduction to Personalized Medicines as well as Adoption of Stem Cell Therapy . The Health Care Technology sector in the North America` region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Thermo Fisher Scientific Inc. (United States), Bio-Rad Laboratories Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Qiagen N.V. (Germany), Immucor Inc. (United States), Biomerieux SA (France), Illumina Inc. (United States), Becton Dickinson and Company (United States), Caredx Inc. (United States) and Genome Diagnostics B.V. (Gendx) (Netherlands) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

At NHS Blood and Transplant held on 5 August 2018, Interim Director of Organ Donation and Transplantation, Anthony Clarkson has said that the decision on organ transplant legislation in the United Kingdom was a matter for Parliament and any changes in the regulations can only take place if the parliament agrees to them. Under the proposed system, the person should either be a donor or he/she should make it clear that they don’t want to donate. According to him, more than 411 people are dead over the last couple of years due to the shortage of donors. Thus, has concluded that the UK government will always favor the organ donor to minimize the demand-supply gap.

Regulatory Insights:
The European Action Plan on Organ Donation and Transplantation (2009-2015) has Strengthened Cooperation between Member States Search for available translations and assists European countries in enhancing transplant systems, addressing the shortage of organs and improving the quality and safety of transplant products. It has set a common direction for European countries to strengthen their national transplant activities and served as the basis for many EU-funded actions. Over the six year period (2009-2015), European countries has increased additional transplants by 4,600 per year.

Market Drivers
  • Growing Instances of Organ Failures with Escalating Chronic Failures
  • Increasing Demand for Pre Transplantation Diagnostics

Market Trend
  • Introduction to Personalized Medicines as well as Adoption of Stem Cell Therapy
  • Growing Adoption of Next Generation Sequencing Technology

Restraints
  • Complexities and Risks Associated with Organ Transplantation
  • Comparatively Expensive Transplant Diagnostics Services

Opportunities
Rising Awareness about Technologically Advanced Transplantation Diagnostics and Increasing Number of Organ Donors across the Globe
Challenges
Instability in Demand for Required Transplantable Organs and Organ Donors and Complex Donor and Recipient Screening

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Transplant Diagnostics Study Sheds Light on
— The Transplant Diagnostics Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Transplant Diagnostics industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Transplant Diagnostics industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Instrument
  • Reagent
  • Software
By Application
  • Human Leukocyte Antigen (HLA)
  • Blood Profile
  • Pathogen Detection
By Organ Type
  • Heart
  • Kidney
  • Liver
  • Stem Cell

By Technology
  • Molecular Assay Technologies
  • Non-Molecular Assay Technologies

By Screening Method
  • Pre Transplantation Screening
  • Post Transplantation Screening

By End User
  • Hospital & Transplant Centers
  • Commercial Service Providers
  • Academics & Research Laboratories

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Instances of Organ Failures with Escalating Chronic Failures
      • 3.2.2. Increasing Demand for Pre Transplantation Diagnostics
    • 3.3. Market Challenges
      • 3.3.1. Instability in Demand for Required Transplantable Organs and Organ Donors
      • 3.3.2. Complex Donor and Recipient Screening
    • 3.4. Market Trends
      • 3.4.1. Introduction to Personalized Medicines as well as Adoption of Stem Cell Therapy
      • 3.4.2. Growing Adoption of Next Generation Sequencing Technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Transplant Diagnostics, by Type, Application, Organ Type, Technology, Screening Method, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Transplant Diagnostics (Value)
      • 5.2.1. Global Transplant Diagnostics by: Type (Value)
        • 5.2.1.1. Instrument
        • 5.2.1.2. Reagent
        • 5.2.1.3. Software
      • 5.2.2. Global Transplant Diagnostics by: Application (Value)
        • 5.2.2.1. Human Leukocyte Antigen (HLA)
        • 5.2.2.2. Blood Profile
        • 5.2.2.3. Pathogen Detection
      • 5.2.3. Global Transplant Diagnostics by: Organ Type (Value)
        • 5.2.3.1. Heart
        • 5.2.3.2. Kidney
        • 5.2.3.3. Liver
        • 5.2.3.4. Stem Cell
      • 5.2.4. Global Transplant Diagnostics by: Technology (Value)
        • 5.2.4.1. Molecular Assay Technologies
        • 5.2.4.2. Non-Molecular Assay Technologies
      • 5.2.5. Global Transplant Diagnostics by: Screening Method (Value)
        • 5.2.5.1. Pre Transplantation Screening
        • 5.2.5.2. Post Transplantation Screening
      • 5.2.6. Global Transplant Diagnostics by: End User (Value)
        • 5.2.6.1. Hospital & Transplant Centers
        • 5.2.6.2. Commercial Service Providers
        • 5.2.6.3. Academics & Research Laboratories
      • 5.2.7. Global Transplant Diagnostics Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Transplant Diagnostics (Price)
      • 5.3.1. Global Transplant Diagnostics by: Type (Price)
  • 6. Transplant Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bio-Rad Laboratories Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Qiagen N.V. (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Immucor Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biomerieux SA (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Illumina Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Becton Dickinson and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Caredx Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Genome Diagnostics B.V. (Gendx) (Netherlands)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Transplant Diagnostics Sale, by Type, Application, Organ Type, Technology, Screening Method, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Transplant Diagnostics (Value)
      • 7.2.1. Global Transplant Diagnostics by: Type (Value)
        • 7.2.1.1. Instrument
        • 7.2.1.2. Reagent
        • 7.2.1.3. Software
      • 7.2.2. Global Transplant Diagnostics by: Application (Value)
        • 7.2.2.1. Human Leukocyte Antigen (HLA)
        • 7.2.2.2. Blood Profile
        • 7.2.2.3. Pathogen Detection
      • 7.2.3. Global Transplant Diagnostics by: Organ Type (Value)
        • 7.2.3.1. Heart
        • 7.2.3.2. Kidney
        • 7.2.3.3. Liver
        • 7.2.3.4. Stem Cell
      • 7.2.4. Global Transplant Diagnostics by: Technology (Value)
        • 7.2.4.1. Molecular Assay Technologies
        • 7.2.4.2. Non-Molecular Assay Technologies
      • 7.2.5. Global Transplant Diagnostics by: Screening Method (Value)
        • 7.2.5.1. Pre Transplantation Screening
        • 7.2.5.2. Post Transplantation Screening
      • 7.2.6. Global Transplant Diagnostics by: End User (Value)
        • 7.2.6.1. Hospital & Transplant Centers
        • 7.2.6.2. Commercial Service Providers
        • 7.2.6.3. Academics & Research Laboratories
      • 7.2.7. Global Transplant Diagnostics Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Transplant Diagnostics (Price)
      • 7.3.1. Global Transplant Diagnostics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Transplant Diagnostics: by Type(USD Billion)
  • Table 2. Transplant Diagnostics Instrument , by Region USD Billion (2015-2020)
  • Table 3. Transplant Diagnostics Reagent , by Region USD Billion (2015-2020)
  • Table 4. Transplant Diagnostics Software , by Region USD Billion (2015-2020)
  • Table 5. Transplant Diagnostics: by Application(USD Billion)
  • Table 6. Transplant Diagnostics Human Leukocyte Antigen (HLA) , by Region USD Billion (2015-2020)
  • Table 7. Transplant Diagnostics Blood Profile , by Region USD Billion (2015-2020)
  • Table 8. Transplant Diagnostics Pathogen Detection , by Region USD Billion (2015-2020)
  • Table 9. Transplant Diagnostics: by Organ Type(USD Billion)
  • Table 10. Transplant Diagnostics Heart , by Region USD Billion (2015-2020)
  • Table 11. Transplant Diagnostics Kidney , by Region USD Billion (2015-2020)
  • Table 12. Transplant Diagnostics Liver , by Region USD Billion (2015-2020)
  • Table 13. Transplant Diagnostics Stem Cell , by Region USD Billion (2015-2020)
  • Table 14. Transplant Diagnostics: by Technology(USD Billion)
  • Table 15. Transplant Diagnostics Molecular Assay Technologies , by Region USD Billion (2015-2020)
  • Table 16. Transplant Diagnostics Non-Molecular Assay Technologies , by Region USD Billion (2015-2020)
  • Table 17. Transplant Diagnostics: by Screening Method(USD Billion)
  • Table 18. Transplant Diagnostics Pre Transplantation Screening , by Region USD Billion (2015-2020)
  • Table 19. Transplant Diagnostics Post Transplantation Screening , by Region USD Billion (2015-2020)
  • Table 20. Transplant Diagnostics: by End User(USD Billion)
  • Table 21. Transplant Diagnostics Hospital & Transplant Centers , by Region USD Billion (2015-2020)
  • Table 22. Transplant Diagnostics Commercial Service Providers , by Region USD Billion (2015-2020)
  • Table 23. Transplant Diagnostics Academics & Research Laboratories , by Region USD Billion (2015-2020)
  • Table 24. South America Transplant Diagnostics, by Country USD Billion (2015-2020)
  • Table 25. South America Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 26. South America Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 27. South America Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 28. South America Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 29. South America Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 30. South America Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 31. Brazil Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 32. Brazil Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 33. Brazil Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 34. Brazil Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 35. Brazil Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 36. Brazil Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 37. Argentina Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 38. Argentina Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 39. Argentina Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 40. Argentina Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 41. Argentina Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 42. Argentina Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 43. Rest of South America Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 44. Rest of South America Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 45. Rest of South America Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 46. Rest of South America Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 47. Rest of South America Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 48. Rest of South America Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 49. Asia Pacific Transplant Diagnostics, by Country USD Billion (2015-2020)
  • Table 50. Asia Pacific Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 51. Asia Pacific Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 52. Asia Pacific Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 53. Asia Pacific Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 54. Asia Pacific Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 55. Asia Pacific Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 56. China Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 57. China Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 58. China Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 59. China Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 60. China Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 61. China Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 62. Japan Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 63. Japan Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 64. Japan Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 65. Japan Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 66. Japan Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 67. Japan Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 68. India Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 69. India Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 70. India Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 71. India Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 72. India Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 73. India Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 74. South Korea Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 75. South Korea Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 76. South Korea Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 77. South Korea Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 78. South Korea Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 79. South Korea Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 80. Taiwan Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 81. Taiwan Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 82. Taiwan Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 83. Taiwan Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 84. Taiwan Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 85. Taiwan Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 86. Australia Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 87. Australia Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 88. Australia Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 89. Australia Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 90. Australia Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 91. Australia Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 92. Rest of Asia-Pacific Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 93. Rest of Asia-Pacific Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 94. Rest of Asia-Pacific Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 95. Rest of Asia-Pacific Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 96. Rest of Asia-Pacific Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 97. Rest of Asia-Pacific Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 98. Europe Transplant Diagnostics, by Country USD Billion (2015-2020)
  • Table 99. Europe Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 100. Europe Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 101. Europe Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 102. Europe Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 103. Europe Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 104. Europe Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 105. Germany Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 106. Germany Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 107. Germany Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 108. Germany Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 109. Germany Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 110. Germany Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 111. France Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 112. France Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 113. France Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 114. France Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 115. France Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 116. France Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 117. Italy Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 118. Italy Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 119. Italy Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 120. Italy Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 121. Italy Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 122. Italy Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 123. United Kingdom Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 124. United Kingdom Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 125. United Kingdom Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 126. United Kingdom Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 127. United Kingdom Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 128. United Kingdom Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 129. Netherlands Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 130. Netherlands Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 131. Netherlands Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 132. Netherlands Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 133. Netherlands Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 134. Netherlands Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 135. Rest of Europe Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 136. Rest of Europe Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 137. Rest of Europe Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 138. Rest of Europe Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 139. Rest of Europe Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 140. Rest of Europe Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 141. MEA Transplant Diagnostics, by Country USD Billion (2015-2020)
  • Table 142. MEA Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 143. MEA Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 144. MEA Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 145. MEA Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 146. MEA Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 147. MEA Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 148. Middle East Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 149. Middle East Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 150. Middle East Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 151. Middle East Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 152. Middle East Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 153. Middle East Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 154. Africa Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 155. Africa Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 156. Africa Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 157. Africa Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 158. Africa Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 159. Africa Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 160. North America Transplant Diagnostics, by Country USD Billion (2015-2020)
  • Table 161. North America Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 162. North America Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 163. North America Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 164. North America Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 165. North America Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 166. North America Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 167. United States Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 168. United States Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 169. United States Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 170. United States Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 171. United States Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 172. United States Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 173. Canada Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 174. Canada Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 175. Canada Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 176. Canada Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 177. Canada Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 178. Canada Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 179. Mexico Transplant Diagnostics, by Type USD Billion (2015-2020)
  • Table 180. Mexico Transplant Diagnostics, by Application USD Billion (2015-2020)
  • Table 181. Mexico Transplant Diagnostics, by Organ Type USD Billion (2015-2020)
  • Table 182. Mexico Transplant Diagnostics, by Technology USD Billion (2015-2020)
  • Table 183. Mexico Transplant Diagnostics, by Screening Method USD Billion (2015-2020)
  • Table 184. Mexico Transplant Diagnostics, by End User USD Billion (2015-2020)
  • Table 185. Transplant Diagnostics: by Type(USD/Units)
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Transplant Diagnostics: by Type(USD Billion)
  • Table 197. Transplant Diagnostics Instrument , by Region USD Billion (2021-2026)
  • Table 198. Transplant Diagnostics Reagent , by Region USD Billion (2021-2026)
  • Table 199. Transplant Diagnostics Software , by Region USD Billion (2021-2026)
  • Table 200. Transplant Diagnostics: by Application(USD Billion)
  • Table 201. Transplant Diagnostics Human Leukocyte Antigen (HLA) , by Region USD Billion (2021-2026)
  • Table 202. Transplant Diagnostics Blood Profile , by Region USD Billion (2021-2026)
  • Table 203. Transplant Diagnostics Pathogen Detection , by Region USD Billion (2021-2026)
  • Table 204. Transplant Diagnostics: by Organ Type(USD Billion)
  • Table 205. Transplant Diagnostics Heart , by Region USD Billion (2021-2026)
  • Table 206. Transplant Diagnostics Kidney , by Region USD Billion (2021-2026)
  • Table 207. Transplant Diagnostics Liver , by Region USD Billion (2021-2026)
  • Table 208. Transplant Diagnostics Stem Cell , by Region USD Billion (2021-2026)
  • Table 209. Transplant Diagnostics: by Technology(USD Billion)
  • Table 210. Transplant Diagnostics Molecular Assay Technologies , by Region USD Billion (2021-2026)
  • Table 211. Transplant Diagnostics Non-Molecular Assay Technologies , by Region USD Billion (2021-2026)
  • Table 212. Transplant Diagnostics: by Screening Method(USD Billion)
  • Table 213. Transplant Diagnostics Pre Transplantation Screening , by Region USD Billion (2021-2026)
  • Table 214. Transplant Diagnostics Post Transplantation Screening , by Region USD Billion (2021-2026)
  • Table 215. Transplant Diagnostics: by End User(USD Billion)
  • Table 216. Transplant Diagnostics Hospital & Transplant Centers , by Region USD Billion (2021-2026)
  • Table 217. Transplant Diagnostics Commercial Service Providers , by Region USD Billion (2021-2026)
  • Table 218. Transplant Diagnostics Academics & Research Laboratories , by Region USD Billion (2021-2026)
  • Table 219. South America Transplant Diagnostics, by Country USD Billion (2021-2026)
  • Table 220. South America Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 221. South America Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 222. South America Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 223. South America Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 224. South America Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 225. South America Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 226. Brazil Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 227. Brazil Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 228. Brazil Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 229. Brazil Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 230. Brazil Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 231. Brazil Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 232. Argentina Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 233. Argentina Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 234. Argentina Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 235. Argentina Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 236. Argentina Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 237. Argentina Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 238. Rest of South America Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 239. Rest of South America Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 240. Rest of South America Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 241. Rest of South America Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 242. Rest of South America Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 243. Rest of South America Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 244. Asia Pacific Transplant Diagnostics, by Country USD Billion (2021-2026)
  • Table 245. Asia Pacific Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 246. Asia Pacific Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 247. Asia Pacific Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 248. Asia Pacific Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 249. Asia Pacific Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 250. Asia Pacific Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 251. China Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 252. China Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 253. China Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 254. China Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 255. China Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 256. China Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 257. Japan Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 258. Japan Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 259. Japan Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 260. Japan Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 261. Japan Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 262. Japan Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 263. India Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 264. India Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 265. India Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 266. India Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 267. India Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 268. India Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 269. South Korea Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 270. South Korea Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 271. South Korea Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 272. South Korea Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 273. South Korea Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 274. South Korea Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 275. Taiwan Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 276. Taiwan Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 277. Taiwan Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 278. Taiwan Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 279. Taiwan Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 280. Taiwan Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 281. Australia Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 282. Australia Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 283. Australia Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 284. Australia Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 285. Australia Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 286. Australia Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 287. Rest of Asia-Pacific Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 288. Rest of Asia-Pacific Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 289. Rest of Asia-Pacific Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 290. Rest of Asia-Pacific Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 291. Rest of Asia-Pacific Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 292. Rest of Asia-Pacific Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 293. Europe Transplant Diagnostics, by Country USD Billion (2021-2026)
  • Table 294. Europe Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 295. Europe Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 296. Europe Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 297. Europe Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 298. Europe Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 299. Europe Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 300. Germany Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 301. Germany Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 302. Germany Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 303. Germany Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 304. Germany Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 305. Germany Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 306. France Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 307. France Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 308. France Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 309. France Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 310. France Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 311. France Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 312. Italy Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 313. Italy Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 314. Italy Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 315. Italy Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 316. Italy Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 317. Italy Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 318. United Kingdom Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 319. United Kingdom Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 320. United Kingdom Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 321. United Kingdom Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 322. United Kingdom Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 323. United Kingdom Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 324. Netherlands Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 325. Netherlands Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 326. Netherlands Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 327. Netherlands Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 328. Netherlands Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 329. Netherlands Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 330. Rest of Europe Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 331. Rest of Europe Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 332. Rest of Europe Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 333. Rest of Europe Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 334. Rest of Europe Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 335. Rest of Europe Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 336. MEA Transplant Diagnostics, by Country USD Billion (2021-2026)
  • Table 337. MEA Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 338. MEA Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 339. MEA Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 340. MEA Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 341. MEA Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 342. MEA Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 343. Middle East Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 344. Middle East Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 345. Middle East Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 346. Middle East Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 347. Middle East Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 348. Middle East Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 349. Africa Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 350. Africa Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 351. Africa Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 352. Africa Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 353. Africa Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 354. Africa Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 355. North America Transplant Diagnostics, by Country USD Billion (2021-2026)
  • Table 356. North America Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 357. North America Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 358. North America Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 359. North America Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 360. North America Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 361. North America Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 362. United States Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 363. United States Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 364. United States Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 365. United States Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 366. United States Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 367. United States Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 368. Canada Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 369. Canada Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 370. Canada Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 371. Canada Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 372. Canada Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 373. Canada Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 374. Mexico Transplant Diagnostics, by Type USD Billion (2021-2026)
  • Table 375. Mexico Transplant Diagnostics, by Application USD Billion (2021-2026)
  • Table 376. Mexico Transplant Diagnostics, by Organ Type USD Billion (2021-2026)
  • Table 377. Mexico Transplant Diagnostics, by Technology USD Billion (2021-2026)
  • Table 378. Mexico Transplant Diagnostics, by Screening Method USD Billion (2021-2026)
  • Table 379. Mexico Transplant Diagnostics, by End User USD Billion (2021-2026)
  • Table 380. Transplant Diagnostics: by Type(USD/Units)
  • Table 381. Research Programs/Design for This Report
  • Table 382. Key Data Information from Secondary Sources
  • Table 383. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Transplant Diagnostics: by Type USD Billion (2015-2020)
  • Figure 5. Global Transplant Diagnostics: by Application USD Billion (2015-2020)
  • Figure 6. Global Transplant Diagnostics: by Organ Type USD Billion (2015-2020)
  • Figure 7. Global Transplant Diagnostics: by Technology USD Billion (2015-2020)
  • Figure 8. Global Transplant Diagnostics: by Screening Method USD Billion (2015-2020)
  • Figure 9. Global Transplant Diagnostics: by End User USD Billion (2015-2020)
  • Figure 10. South America Transplant Diagnostics Share (%), by Country
  • Figure 11. Asia Pacific Transplant Diagnostics Share (%), by Country
  • Figure 12. Europe Transplant Diagnostics Share (%), by Country
  • Figure 13. MEA Transplant Diagnostics Share (%), by Country
  • Figure 14. North America Transplant Diagnostics Share (%), by Country
  • Figure 15. Global Transplant Diagnostics: by Type USD/Units (2015-2020)
  • Figure 16. Global Transplant Diagnostics share by Players 2020 (%)
  • Figure 17. Global Transplant Diagnostics share by Players (Top 3) 2020(%)
  • Figure 18. Global Transplant Diagnostics share by Players (Top 5) 2020(%)
  • Figure 19. BCG Matrix for key Companies
  • Figure 20. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Bio-Rad Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Bio-Rad Laboratories Inc. (United States) Revenue: by Geography 2020
  • Figure 24. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2020
  • Figure 26. Qiagen N.V. (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Qiagen N.V. (Germany) Revenue: by Geography 2020
  • Figure 28. Immucor Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Immucor Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Biomerieux SA (France) Revenue, Net Income and Gross profit
  • Figure 31. Biomerieux SA (France) Revenue: by Geography 2020
  • Figure 32. Illumina Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Illumina Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Becton Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 35. Becton Dickinson and Company (United States) Revenue: by Geography 2020
  • Figure 36. Caredx Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Caredx Inc. (United States) Revenue: by Geography 2020
  • Figure 38. Genome Diagnostics B.V. (Gendx) (Netherlands) Revenue, Net Income and Gross profit
  • Figure 39. Genome Diagnostics B.V. (Gendx) (Netherlands) Revenue: by Geography 2020
  • Figure 40. Global Transplant Diagnostics: by Type USD Billion (2021-2026)
  • Figure 41. Global Transplant Diagnostics: by Application USD Billion (2021-2026)
  • Figure 42. Global Transplant Diagnostics: by Organ Type USD Billion (2021-2026)
  • Figure 43. Global Transplant Diagnostics: by Technology USD Billion (2021-2026)
  • Figure 44. Global Transplant Diagnostics: by Screening Method USD Billion (2021-2026)
  • Figure 45. Global Transplant Diagnostics: by End User USD Billion (2021-2026)
  • Figure 46. South America Transplant Diagnostics Share (%), by Country
  • Figure 47. Asia Pacific Transplant Diagnostics Share (%), by Country
  • Figure 48. Europe Transplant Diagnostics Share (%), by Country
  • Figure 49. MEA Transplant Diagnostics Share (%), by Country
  • Figure 50. North America Transplant Diagnostics Share (%), by Country
  • Figure 51. Global Transplant Diagnostics: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific Inc. (United States)
  • Bio-Rad Laboratories Inc. (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Qiagen N.V. (Germany)
  • Immucor Inc. (United States)
  • Biomerieux SA (France)
  • Illumina Inc. (United States)
  • Becton Dickinson and Company (United States)
  • Caredx Inc. (United States)
  • Genome Diagnostics B.V. (Gendx) (Netherlands)
Additional players considered in the study are as follows:
Luminex Corporation (United States) , Becton Dickinson and Company (United States) , Hologic (United States)
Select User Access Type

Key Highlights of Report


Nov 2021 242 Pages 64 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global and Regional Transplant Diagnostics Quantitative research analysis
Global and Regional Transplant Diagnostics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Transplant Diagnostics market is expected to see a CAGR of 7.9% during projected year 2020 to 2026.
Top performing companies in the Global Transplant Diagnostics market are Thermo Fisher Scientific Inc. (United States), Bio-Rad Laboratories Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Qiagen N.V. (Germany), Immucor Inc. (United States), Biomerieux SA (France), Illumina Inc. (United States), Becton Dickinson and Company (United States), Caredx Inc. (United States) and Genome Diagnostics B.V. (Gendx) (Netherlands), to name a few.
North America` is dominating the Transplant Diagnostics Market.

Know More About Global and Regional Transplant Diagnostics Report?

Have a Query? Click Here

Other Related Reports

Anesthesia Machines Comprehensive Study by Type (Mobile Anesthesia Machines, Fixed Anesthesia Machines), Application (Operating Room , Intensive Care Unit , Others), End User (Human, Animal) Players ...
$ 3500
Medical Device Connectivity Comprehensive Study by Technology (Wired Technologies, Wireless Technologies, Hybrid Technologies), Service (Support and Maintenance, Implementation and Integration, Train...
$ 3750
Clinical Trial Imaging Comprehensive Study by Type (Services (Clinical Trial Design and Consultation Services, Reading and Analytical Services, Operational Imaging Services, System and Technology Sup...
$ 3750
Knee Replacement Implants Comprehensive Study by Procedure (Total Knee Replacement, Partial Knee Replacement, Revision Knee Replacement), Component (Fixed Bearing Implants, Mobile Bearing Implants)...
$ 3650
DNA Sequencing Instruments Comprehensive Study by Type (Consumable, Instrument, Service), Application (Biomarkers and Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Forensics, Other...
$ 3750
Artificial Joints Comprehensive Study by Type (Cemented Joints, Non-Cemented Joints), Application (Artificial Joints of Knee, Artificial Joints of Hip, Artificial Joints of Shoulder, Other), Material...
$ 3450